News Features ‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry Michael O'Riordan January 10, 2020
News Features Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019 Todd Neale December 10, 2019
News Conference News AHA 2019 Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure Shelley Wood November 22, 2019
News Conference News ESC 2019 PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen Todd Neale September 01, 2019
News Daily News Most Cardiovascular Drugs Can Be Safely Used in Pregnancy, Review Suggests Todd Neale February 01, 2019
News Conference News AHA 2018 EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits Michael O'Riordan November 16, 2018
News Conference News AHA 2018 DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors Todd Neale November 10, 2018
News Conference News ESC 2018 COMMANDER HF: Low-Dose Rivaroxaban Flops in Heart Failure Todd Neale August 27, 2018
News Conference News CANVAS Analysis Provides Heart Failure Reassurances for Canagliflozin Michael O'Riordan March 16, 2018
News Daily News Heart Failure Risk Following 'Silent' MI Warrants Scrutiny: ARIC Analysis Caitlin E. Cox January 08, 2018